Why the study?
Do second-line measures (midodrine, fludrocortisone, beta-blockers, SSRIs) improve outcomes in patients with vasovagal syncope refractory to first-line measures?
Do second-line measures (midodrine, fludrocortisone, beta-blockers, SSRIs) improve outcomes in patients with vasovagal syncope refractory to first-line measures?
Answers are grounded in this paper and cite their sources.
Evidence for second-line pharmacological therapies in refractory vasovagal syncope remains limited.
Second-line measures include midodrine, fludrocortisone, beta-blockers, and SSRIs, but evidence is limited.
No takes yet. Share an insight, caveat, or question.
Hutt et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: